The United States Government As Represented by the Department of Veterans Affairs

Indiana University

Natalia Bogatcheva

Keith Leonard March

Matthias Alexander Clauss

EMAPII is a monocyte- and endothelial cell-activating protein with prominent pro-apoptotic activity on endothelial and epithelial cells. Provided herein are compositions and methods for treating or preventing endothelial and epithelial apoptosis induced by EMAPII. More particularly, provided herein are compositions and methods for treating or preventing Influenza A virus (IAV)-induced weight loss, impairment of blood oxygenation, lung edema, and endothelial/epithelial apoptosis associated with IAV infections. In addition, anti-EMAPII therapy provides a novel complementary treatment strategy to existing anti-viral and anti-inflammatory approaches.

Emapii neutralizing antibody limits influenza A virus (IAV)-induced lung injury

Disclosed herein is that the systemic administration of ASC conditioned media diminished LPS-induced lung injury by inhibiting epithelial permeability, neutrophil inflammatory response, and secretion of pro-inflammatory TNF&#x3b1;. It is also shown that ARDS lung is able to retain IV-delivered ASC for a substantial amount of time, with no evidence of the significant cell distribution to other organs at this time point. These findings provide optimization of cell-based and cell-free therapy for the treatment of ARDS, including occurrences of ARDS caused by upper respiratory tract infections such as SARS and MERS.

Growing community of inventors

Westfield, IN, United States of America

Natalia Bogatcheva